Sr. FDA official calls Uniqure's Huntington's disease treatment a failure

Group 1 - A senior FDA official labeled Uniqure's experimental Huntington's disease treatment as a "failed product," raising concerns about the future of its gene therapy [1] - The statement from the FDA official was made during a media conference call, indicating a significant setback for Uniqure [1] - This development adds to the uncertainty surrounding the efficacy and market potential of Uniqure's gene therapy for Huntington's disease [1]